3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
11
Carcinoma, Hepatocellular
7
Colorectal Neoplasms
5
Neoplasm Metastasis
4
Esophageal Squamous Cell Carcinoma
4
Advanced Solid Tumor
4
Solid Tumor
3
Small Cell Lung Carcinoma
3
Esophageal Neoplasms
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Melanoma
2
Lung Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Transitional Cell
2
Advanced Solid Tumour
2
Unresectable Stage III Non-small Cell Lung Cancer
1
Triple Negative Breast Neoplasms
1
Skin Neoplasms
1
Simpson-Golabi-Behmel syndrome
1
Rectal Neoplasms
1
Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Nasopharyngeal Carcinoma
1
Metastatic Solid Tumors
1
MSI-H/dMMR Solid Tumors
1
Interventions
Gemcitabine
29
pembrolizumab
20
Cisplatin
20
Magnetic Resonance Spectroscopy
17
Specimen Handling
16
Mitomycin
10
enfortumab vedotin
9
durvalumab
9
Cystoscopy
9
avelumab
8
Nivolumab
8
Fluorouracil
8
Carboplatin
8
Radiation
7
Cystectomy
6
atezolizumab
5
Transurethral Resection of Bladder
5
Radiotherapy
5
Mitozytrex
5
Docetaxel
5
Biopsy
5
tremelimumab
4
sacituzumab govitecan
4
erdafitinib
4
dehydroftorafur
4
Platinum
4
Immunoglobulin G
4
Disulfides
4
1,2-diaminocyclohexaneplatinum II citrate
4
disitamab vedotin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
tislelizumab
×
90 days
×
Clear all
No trials found.